Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1 clinical trial in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

 

 


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... GNVC ) announced that Adel A.F. Mahmoud, M.D., ... the Company,s Board of Directors at its annual meeting of ... "Drs. Mahmoud and Connor bring a wealth of experience, especially ... expand the breadth and scope of our vaccine programs there ...
... June 22, 2011 Genesis Biopharma, Inc. (OTC/BB: GNBP), ... that it will hold a conference call with the ... Eastern (9:00 a.m. Pacific).  The Company,s Chairman and Chief ... on the business, and discuss the clinical and commercial ...
Cached Medicine Technology:GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 2GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 3GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors 4Genesis Biopharma to Hold Business Update Conference Call on June 29 2
(Date:8/28/2014)... TX (PRWEB) August 28, 2014 After ... Dr. Paul Vitenas is excited to announce the ... of its kind in any city, Mirror Mirror Beauty ... building. , Situated on the corner of Richmond and ... modern architecture, luxurious amenities, and cutting-edge technology in a ...
(Date:8/28/2014)... Having greater amounts of yellow pigment in your eyes ... hazy conditions, a new study reports. In a ... in order to test the distance vision of people ... pigment) in their eyes. The volunteers had widely ... the nutrients lutein and zeaxanthin, according to the researchers, ...
(Date:8/28/2014)... The Foundation for Women’s Cancer ... September by alerting women to the link between obesity ... symptoms of endometrial cancer. , Endometrial cancer is ... common cancer. More than 52,600 will learn of a ... women with weight management challenges to know the early ...
(Date:8/28/2014)... Diego, CA (PRWEB) August 28, 2014 Vitals, ... has named Dr. Sabrina Fabi of Cosmetic Laser Dermatology one ... allows hundreds of thousands of patients to share their doctor ... including bedside manner, face time, and follow-ups. The Vitals Top ... in California, Dr. Fabi was ranked one of the highest ...
(Date:8/28/2014)... 28, 2014 Dr. Bryan McIntosh of ... ebook guide to the tummy tuck cosmetic procedure, ... the procedure itself, and how to recover well afterwards. ... explanations. Dr. McIntosh also discusses how to have accurate ... that the procedure is as successful as possible. , ...
Breaking Medicine News(10 mins):Health News:Mirror Mirror Beauty Boutique to Welcome Its First Patients 2Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Foundation for Women's Cancer Alerts Women to Link Between Obesity and Endometrial Cancer 2Health News:Dr. Sabrina Fabi of Cosmetic Laser Dermatology Recognized as Vitals Top 10 Doctor 2Health News:The Ultimate Guide to the Tummy Tuck Surgery eBook is Released by Dr. Bryan McIntosh 2
... networks begin with one altruistic living donor, study explains, ... one healthy young man stepped forward, willing to give ... years later, 10 people had received new kidneys from ... donation started the first nonsimultaneous, extended altruistic-donor (NEAD) chain. ...
... report finds , , WEDNESDAY, March 11 (HealthDay News) -- Thousands ... by atmospheric ozone, a new study finds. , The greatest ... such as Los Angeles, which has one of the highest ... 25 percent to 30 percent higher annual risk of dying ...
... The Coalition for Ethical Imaging (CEI), a grassroots ... in Texas, has announced its support for Senate Bill ... bill in the House, House Bill 2599 by Rep. ... patient care and safety in the state of Texas ...
... BALTIMORE, March 11 The Open Society Institute,s Closing ... exist for the new Director of the Office of ... the United States, approach to the problem of addiction. ... Gil Kerlikowske,s official nomination as the nation,s "drug czar," ...
... Kidney Month Briefing Reveals Majority of New Kidney Failure ... Disproportionate Rates -WASHINGTON, March 11 Kidney Care Partners ... dialysis professionals, care providers and manufacturers working together to ... disease and kidney failure -- in partnership with the ...
... The American Association of Oral and Maxillofacial Surgeons ... on her recent introduction of H.R. 1339, the ... , which would require insurance plans, including those which ... (ERISA) , that provide surgical benefits, to cover reconstructive ...
Cached Medicine News:Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3Health News:Closing the Addiction Treatment Gap Initiative Highlights Opportunities for New 'Drug Czar' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 2Health News:Kidney Care Partners and National Minority Quality Forum Call for Prevention Programs in Disease 'Hot Spots' 3Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 2Health News:Oral and Maxillofacial Surgeons Applaud Congresswoman McCarthy's Legislation to Require Insurance Coverage for Children With Congenital Deformities 3
The Osteomark NTx Point of Care (POC)device allows physicians to monitor their patients response to anti-resorptive drugs as early as 3-6 months from starting treatment. Osteomark NTx shows you and y...
... 50 analyzer is an ... offices and smaller laboratories ... of state-of-the-art instrument-based testing ... efficient way to obtain ...
... Hemoglobin Test Systems provide ... quantitative hemoglobin results with ... a large hematology analyzer. ... of either the B-Hemoglobin ...
... a qualitative immunoassay for urinary albumin that ... This albumin specific, CLIA Waived test has ... of 95%, and gives accurate results in ... up to 8 hours. Since early detection ...
Medicine Products: